Episodic migraine headaches affect 10-20% of the world population and are among the top four disabling neurological conditions (WHO). Migraines account for an estimated 30 million days of lost productivity at a cost of up to $17 billion per year in the US. Approximately half of migraine patients suffer severe pain and require bed rest. Migraines affect 28 million Americans; one of every four American households has a family member who suffers from...
Osteoarthritis, a chronic joint disease causing pain and disability most commonly of the hip and knee, afflicts 17% of the US population. It is a $60 billion per year burden on the healthcare system and occurs in about 40% of the population over the age of 65. Advanced OA accounts for 85% of knee replacement surgeries among Medicare recipients. Fast symptomatic relief of acute pain associated with OA flare is a major market opportunity
EP receptors are a group of prostanoid receptor subtypes (EP 1 – EP4) that are linked through G-proteins to different signalling pathways involved in a diverse range of biological systems. These receptors are excellent druggable targets for the development of small molecule drugs. Ariel is developing antagonists to the EP4 receptor as a therapeutic platform for major unmet medical needs where drug selectivity, safety and potency are important.
Ariel Pharmaceuticals, Inc. is a private, development-stage specialty pharmaceutical company focused on development and commercialization of products for major unmet medical needs. We are currently developing two drugs intended to meet unmet medical needs in migraine and osteoarthritis.
Learn MoreWe have an experienced drug development team with core competencies in preclinical assessment, global clinical development, manufacturing and commercialization. To further leverage our own in-house development programs and build a well-balanced portfolio of products, we seek to acquire or partner new product opportunities.
Learn More